ClinicalTrials.gg
CompletedNCT01227668Updated Nov 3, 2026Results posted

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

A Phase 4 interventional study of Aripiprazole and Placebo in Irritability Associated With Autistic Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 38 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Updated Nov 3, 2026Posted results revisedSponsor changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing aripiprazole in Autistic Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Autistic Disorder.

Enrollment
3rd of 15
215 · median 81
Started
2011
with 1 other
Phase 4
4 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
4 of 15
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 15 studies testing aripiprazole in Autistic Disorder, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 4, and was the 11th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

None of the 15 studies testing aripiprazole in Autistic Disorder is open now. The open studies under Autistic Disorder, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing aripiprazole in Autistic Disorder as a file.
02

Study summary

The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.

03

Conditions studied

  • Irritability Associated With Autistic Disorder

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
  • Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
  • Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
  • Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
  • An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
  • Mental age of at least 24 months

Key Exclusion Criteria:

  • Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
  • Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a response.
  • Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
  • Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
  • History of neuroleptic malignant syndrome
  • At significant risk for suicide based on history or routine psychiatric status examination
  • A seizure within the past year
  • History of severe head trauma or stroke
  • History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Weight lower than 15 kg
  • Known allergy or to aripiprazole or other dihidrocarbostyrils
  • History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • Any other medically significant abnormal laboratory test or vital sign result or finding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    Drug: Aripiprazole

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Tablets, oral, 2-15 mg, once daily, 13-42 weeks

    Also known as: BMS-337039, Abilify

  • DrugPlacebo

    Tablets, oral, 0 mg, once daily, 16 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Relapsing by Week 16

    Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a\&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a\&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

    Time frame: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Secondary outcomes

  1. Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])

    ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

    Time frame: From Baseline (end of Phase 1) to Week 16 of Phase 2

  2. Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])

    CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to \<=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

    Time frame: From Baseline (end of Phase 1) to Week 16 of Phase 2

  3. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Up to 26 weeks

Other outcomes

  1. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

07

Results

Posted May 2, 2014

Participant flow

Phase 1 (Stabilization Phase)
Participant flow — Phase 1 (Stabilization Phase)
MilestoneAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)Placebo
Started1570
Received treatment1550
Completed850
Not completed720
Withdrew: Adverse event120
Withdrew: Withdrawal by subject70
Withdrew: Lost to follow-up80
Withdrew: Sponsor's administrative reason110
Withdrew: No longer meets study criteria70
Withdrew: Lack of efficacy250
Withdrew: Poor compliance/noncompliance20
Phase 2 (Randomization Phase)
Participant flow — Phase 2 (Randomization Phase)
MilestoneAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)Placebo
Started4144
Received treatment3943
Completed2219
Not completed1925
Withdrew: Adverse event01
Withdrew: Withdrawal by subject50
Withdrew: Lost to follow-up10
Withdrew: Lack of efficacy1323
Withdrew: Poor compliance/noncompliance01

Outcome measures

PrimaryPercentage of Patients Relapsing by Week 16

Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a\&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a\&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

Time frame:
From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
Reported as:
Number · Percentage of participants
Percentage of Patients Relapsing by Week 16
Percentage of participantsAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)Placebo
Percentage of Patients Relapsing by Week 1632 (NA to NA)50 (42 to NA)
Statistical analysis
  • Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) vs Placebo · Stratified log rank · p = 0.097 · Hazard ratio (hr): 0.57 · 95% CI 0.28 to 1.12
SecondaryAdjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])

ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

Time frame:
From Baseline (end of Phase 1) to Week 16 of Phase 2
Reported as:
Mean · Units on a scale
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Units on a scaleAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)Placebo
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])5.2 ± 1.619.6 ± 1.56
Statistical analysis
  • Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) vs Placebo · ANCOVA · p = 0.051 (For secondary endpoints, hierarchical testing aimed to keep the overall experiment-wise type I error rate to \<=0.05. Difference in chg from BL was tested at 0.05 significance only if APR arm significantly differed vs placebo from primary analysis.) · Mean difference (final values): -4.40 · 95% CI -8.82 to 0.02
SecondaryChange From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])

CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to \<=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

Time frame:
From Baseline (end of Phase 1) to Week 16 of Phase 2
Reported as:
Mean · Units on a scale
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Units on a scaleAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)Placebo
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])4.2 ± 0.264.8 ± 0.26
Statistical analysis
  • Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose) vs Placebo · ANCOVA · p = 0.090 (Treatment diff in chg from BL to endpnt in IS score was tested at 0.05 signif only if ARP arm signif differed vs pb from PA. Thus, if ARP arm signif differed vs pb in IS score, treatment diff in mean CGI-I score at endpnt was tested at 0.05 signfnce.) · Mean difference (final values): -0.6 · 95% CI -1.3 to 0.1
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Up to 26 weeks
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
ParticipantsAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)
Death0
SAEs1
AEs leading to discontinuation13
Other pre-specifiedNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
ParticipantsAripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)Placebo
Death00
SAEs00
AEs leading to discontinuation00
Treatment-related AEs96

Adverse events

Collected over Up to 42 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole, 2-15 mg (Phase 1)0/157 (0%)1/155 (0.6%)112/155 (72.3%)
Aripiprazole, 2-15 mg (Phase 2)0/41 (0%)0/39 (0%)11/39 (28.2%)
Placebo (Phase 2 Only)0/44 (0%)0/43 (0%)5/43 (11.6%)
Most frequent serious events
Most frequent serious events
EventAripiprazole, 2-15 mg (Phase 1)Aripiprazole, 2-15 mg (Phase 2)Placebo (Phase 2 Only)
AggressionPsychiatric disorders1/1550/390/43
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAripiprazole, 2-15 mg (Phase 1)Aripiprazole, 2-15 mg (Phase 2)Placebo (Phase 2 Only)
Weight increasedInvestigations39/1550/390/43
SomnolenceNervous system disorders23/1550/390/43
VomitingGastrointestinal disorders22/1552/392/43
Increased appetiteMetabolism and nutrition disorders20/1551/392/43
Upper respiratory tract infectionInfections and infestations16/1554/391/43
FatigueGeneral disorders13/1551/390/43
InsomniaPsychiatric disorders13/1551/391/43
DiarrhoeaGastrointestinal disorders11/1551/390/43
TremorNervous system disorders10/1551/391/43
NasopharyngitisInfections and infestations9/1551/391/43

Baseline characteristics

All participants who were randomized to receive treatment in Phase 2.

Age, Continuous
Age, Continuous(years)Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)PlaceboTotal
Mean10.1 ± 2.8010.8 ± 2.7710.4 ± 2.79
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)PlaceboTotal
Female11617
Male303868
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aripiprazole, 2-15 mg Once Daily (Titered to Optimum Dose)PlaceboTotal
American Indian or Alaska Native011
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American81119
White312859
Other213
08

Study locations

38 sites
  • Harmonex Neuroscience Research, Inc
    Dothan, Alabama 36303, United States
  • Southwest Autism Research And Resource Center
    Phoenix, Arizona 85006, United States
  • Clinical Innovations, Inc.
    Costa Mesa, California 92626, United States
  • Behavioral Research Specialists, Llc
    Glendale, California 91206, United States
  • Abbey Neuropsychology Clinic
    Palo Alto, California 94306, United States
  • Ucsf - Lppi
    San Francisco, California 94143, United States
  • Stanford University School Of Medicine
    Stanford, California 94305, United States
  • Children'S National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Palm Springs Research Institute
    Hialeah, Florida 33012, United States
  • Florida Clinical Research Center, Llc
    Maitland, Florida 32751, United States
  • Miami Children'S Hospital
    Miami, Florida 33155, United States
  • University Of South Florida
    Tampa, Florida 33613, United States
  • Institute For Behavioral Medicine, Llc
    Smyrna, Georgia 30080, United States
  • Kootenai Behavioral Health Center
    Coeur d'Alene, Idaho 83814, United States
  • Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Lsu Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • Neurocare, Inc.
    Newton, Massachusetts 02459, United States
  • Neurobehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
  • Center For Psychiatry And Behavioral Medicine, Inc
    Las Vegas, Nevada 89128, United States
  • Clinical Research Center Of New Jersey
    Gibbsboro, New Jersey 08026, United States
  • Children'S Specialized Hosp
    Toms River, New Jersey 08755, United States
  • Stony Brook University School Of Medicine
    Stony Brook, New York 11794, United States
  • Unc Chapel Hill
    Chapel Hill, North Carolina 27517, United States
  • Cleveland Clinic
    Cleveland, Ohio 44104, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Nisonger Center
    Columbus, Ohio 43210, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Ou Physician'S Child Study Center
    Oklahoma City, Oklahoma 73117, United States
  • Tulsa Clinical Research, Llc
    Tulsa, Oklahoma 74104, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • Drexel University College Of Medicine
    Philadelphia, Pennsylvania 19124, United States
  • Western Psychiatric Institute And Clinic
    Pittsburgh, Pennsylvania 15203, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Insite Clinical Research
    DeSoto, Texas 75115, United States
  • Ericksen Research And Development
    Clinton, Utah 84015, United States
  • Childrens Specialty Gr., Pllc
    Norfolk, Virginia 23510, United States
  • Virginia Treatment Center For Children
    Richmond, Virginia 23298, United States
09

References and documents

Publications

  • Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2. PubMed 37811711 ↗
  • Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22-30. doi: 10.4088/jcp.13m08500. PubMed 24502859 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2011 to primary completion in Jun 2012, 15 months.

Results were first posted in May 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Oct 25, 2010
StartActual
Mar 7, 2011
Primary completionActual
Jun 20, 2012
CompletionActual
Jun 20, 2012
Results first posted
May 2, 2014
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 3, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 United States)
  • Children'S National Medical Center · Washington D.C., United States
  • Kootenai Behavioral Health Center · Coeur d'Alene, United States
  • Insite Clinical Research · DeSoto, United States
Show 3 removed
  • Children'S National Medical Center · Washington, United States
  • Kootenai Behavioral Health Center · Coeur D'Alene, United States
  • Insite Clinical Research · Desoto, United States
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37811711 ↗
Nov 3, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1Weekly from Week 1 to Week 26 and continuously to end of treatment → Up to 26 weeks
Nov 3, 2026
Title
Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
Nov 3, 2026
Sponsor
Bristol-Myers Squibb→Otsuka Pharmaceutical Development & Commercialization, Inc.
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Posted results revised
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37811711 ↗
    3 sites added, 3 sites removed
    Show 3 added (3 United States)
    • Children'S National Medical Center · Washington D.C., United States
    • Kootenai Behavioral Health Center · Coeur d'Alene, United States
    • Insite Clinical Research · DeSoto, United States
    Show 3 removed
    • Children'S National Medical Center · Washington, United States
    • Kootenai Behavioral Health Center · Coeur D'Alene, United States
    • Insite Clinical Research · Desoto, United States
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1Weekly from Week 1 to Week 26 and continuously to end of treatment → Up to 26 weeks
    Sponsor Bristol-Myers Squibb→Otsuka Pharmaceutical Development & Commercialization, Inc.
    Title Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
    + 7 other changes: verification date, date precision, oversight details, description, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01227668
Responsible party
Sponsor
First posted
Oct 25, 2010
Start date
Mar 7, 2011
Primary completion
Jun 20, 2012
Completion
Jun 20, 2012
Results posted
May 2, 2014
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion